Fundraising Fox

Morphoceuticals

Medford, US · Founded 2020 · Delaware corporation · 1 known investors

Biotech

Founders & leadership

MR
Michael R. HuffordExecutive
JJ
James JensonExecutive
DG
David GillNamed on SEC filing

Board

AP
Alexander PickettBoard director
JBJustin Briggs
Justin Briggsin𝕏Board MemberPartner & VP of Biology at Prime Movers Lab
TH
Tamim Hamad J.J Al-ThaniBoard director
AKAmy Kruse
Amy KruseinBoard directorVenture Partner at Prime Movers Lab
RH
Rosemarie HunzikerBoard director

Investors · 1

Prime Movers Labreported · 3 sourcesJackson · $2M – $30Mvia Amy Kruse · board

Reported raises · per SEC filings

Form D private placements

$13.3M disclosed across 2 rounds · 2023–2024

▶$3.5MraisedOct 2024 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Michael R. HuffordDirector
  • Alexander PickettDirector
  • Justin BriggsDirector
  • Tamim Hamad J.J Al-ThaniDirector
  • Rosemarie HunzikerDirector
  • James JensonExecutive Officer, Director
Offering amount
$5.5M
Amount sold
$3.5M
First sale
Sep 2024
Incorporated
Corporation, Delaware, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$9.8MraisedJan 2023 · 3 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Alexander PickettDirector
  • Michael LevinPromoter
  • David GillExecutive Officer
  • David KaplanPromoter
  • Amy KruseDirector
  • Michael R. HuffordExecutive Officer, Director
  • Rosemarie HunzikerDirector
Offering amount
$9.8M
Amount sold
$9.8M
Proceeds to insiders
$612K
First sale
Jan 2023
Incorporated
Corporation, Delaware, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 3

by search overlap
nChroma Bio10 shared keywordsnChroma Bio develops in vivo targeted delivery and genetic engineering technologies for genetic medicine applications. The company works with academic founders and institutional investors focused on advancing gene therapy treatments.
Metaphorebio10 shared keywordsMetaphore develops a platform that measures biological activity inside cells at scale to design antibody medicines with novel mechanisms of action. The company aims to create antibodies that activate pathways, modulate signaling, and engage multiple targets to treat complex diseases.
Bioworld10 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

Companies competing with Morphoceuticals for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Morphoceuticals: Interview With CEO Jim Jenson About The Tissue Regeneration And Disease Treatment Companypulse2.com · Aug 2025Empowering Healing: Morphoceuticals Secures $3.5 Million in Seed Funding to Pioneer Bioelectric Bioinformatics Technology | SignalBasetrysignalbase.com · Oct 2024Why Prime Movers Lab Invested in Morphoceuticals | by Justin Briggs | Prime Movers Lab | Mediummedium.com · Feb 2023Morphoceuticals raises $8M to advance bioelectrical treatment for regenerating tissues or organsliveforever.club · Feb 2023Morphoceuticals Raises $8 million to Advance Electroceutical Approach to Regenerative Medicine - BioSpacebiospace.com · Feb 2023Morphoceuticals Raises $8M in Seed-2 Fundingfinsmes.com · Feb 2023

Frequently asked questions

Who are Morphoceuticals's investors?
Morphoceuticals's investors include Prime Movers Lab.
How much funding has Morphoceuticals raised?
Morphoceuticals has disclosed $13.3M raised across 2 rounds.
Where is Morphoceuticals headquartered?
Morphoceuticals is headquartered in Medford, US.